Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

• DOI: 10.1200/jco.2016.34.15_suppl.4507
• Publication Date: 2018-09-06T16:29:31Z
• Authors: David F. McDermott; Robert J. Motzer; Michael B. Atkins; Elizabeth R. Plimack; Mario Sznol; Saby George; Charles G. Drake; Brian I. Rini; Toni K. Choueiri; Timothy Kuzel; Jeffrey Alan Sosman; David C. Smith; Ulka N. Vaishampayan; John D. Powderly; Suzanne Louise To...; Huanyu Zhao; Ian M. Waxman; Hans J. Hammers
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

4507Background: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, was recently approved by the FDA for patients with clear-cell aRCC previously treated with anti-angiogenic therap...